JP2011502177A5 - - Google Patents

Info

Publication number

JP2011502177A5

JP2011502177A5 JP2010532406A JP2010532406A JP2011502177A5 JP 2011502177 A5 JP2011502177 A5 JP 2011502177A5 JP 2010532406 A JP2010532406 A JP 2010532406A JP 2010532406 A JP2010532406 A JP 2010532406A JP 2011502177 A5 JP2011502177 A5 JP 2011502177A5

Authority

JP

Japan

Prior art keywords

seq

liposome

therapeutic agent

compound

peptide

Prior art date

2008-11-05

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 239000002502 liposome Substances 0.000 claims 35
• 239000003814 drug Substances 0.000 claims 29
• 229940124597 therapeutic agent Drugs 0.000 claims 29
• 150000001875 compounds Chemical class 0.000 claims 26
• 150000002632 lipids Chemical class 0.000 claims 21
• 108090000765 processed proteins & peptides Proteins 0.000 claims 21
• 239000002202 Polyethylene glycol Substances 0.000 claims 13
• 229920001223 polyethylene glycol Polymers 0.000 claims 13
• LVNGJLRDBYCPGB-LDLOPFEMSA-N (R)-1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-LDLOPFEMSA-N 0.000 claims 10
• 230000001093 anti-cancer Effects 0.000 claims 9
• KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims 6
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 6
• BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 6
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 5
• 230000001225 therapeutic effect Effects 0.000 claims 5
• 190000008236 carboplatin Chemical compound 0.000 claims 4
• 229960004562 carboplatin Drugs 0.000 claims 4
• 102000004190 Enzymes Human genes 0.000 claims 3
• 108090000790 Enzymes Proteins 0.000 claims 3
• ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 3
• 231100000632 Spindle poison Toxicity 0.000 claims 3
• 229930013930 alkaloid Natural products 0.000 claims 3
• 150000003797 alkaloid derivatives Chemical class 0.000 claims 3
• 229940100198 alkylating agent Drugs 0.000 claims 3
• 239000002168 alkylating agent Substances 0.000 claims 3
• 230000000340 anti-metabolite Effects 0.000 claims 3
• 230000000259 anti-tumor effect Effects 0.000 claims 3
• 239000013059 antihormonal agent Substances 0.000 claims 3
• 229940100197 antimetabolite Drugs 0.000 claims 3
• 239000002256 antimetabolite Substances 0.000 claims 3
• 239000003972 antineoplastic antibiotic Substances 0.000 claims 3
• 230000006907 apoptotic process Effects 0.000 claims 3
• 230000008512 biological response Effects 0.000 claims 3
• 231100000433 cytotoxic Toxicity 0.000 claims 3
• 230000001472 cytotoxic effect Effects 0.000 claims 3
• 239000003534 dna topoisomerase inhibitor Substances 0.000 claims 3
• 229960003668 docetaxel Drugs 0.000 claims 3
• 229960004679 doxorubicin Drugs 0.000 claims 3
• 239000002532 enzyme inhibitor Substances 0.000 claims 3
• 229940125532 enzyme inhibitor Drugs 0.000 claims 3
• 239000012634 fragment Substances 0.000 claims 3
• 239000000411 inducer Substances 0.000 claims 3
• 229940043355 kinase inhibitor Drugs 0.000 claims 3
• 239000012528 membrane Substances 0.000 claims 3
• 239000003607 modifier Substances 0.000 claims 3
• 239000003757 phosphotransferase inhibitor Substances 0.000 claims 3
• 239000003504 photosensitizing agent Substances 0.000 claims 3
• 229910052697 platinum Inorganic materials 0.000 claims 3
• 150000004492 retinoid derivatives Chemical class 0.000 claims 3
• 229940044693 topoisomerase inhibitor Drugs 0.000 claims 3
• 206010028980 Neoplasm Diseases 0.000 claims 2
• 201000011510 cancer Diseases 0.000 claims 2
• 239000002872 contrast media Substances 0.000 claims 2
• 239000007791 liquid phase Substances 0.000 claims 2
• 238000000034 method Methods 0.000 claims 2
• 239000012071 phase Substances 0.000 claims 2
• 102000004196 processed proteins & peptides Human genes 0.000 claims 2
• 230000005855 radiation Effects 0.000 claims 2
• 230000007704 transition Effects 0.000 claims 2
• 238000002604 ultrasonography Methods 0.000 claims 2
• 238000010792 warming Methods 0.000 claims 2
• 229940126062 Compound A Drugs 0.000 claims 1
• NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 1
• ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 claims 1
• 125000003275 alpha amino acid group Chemical group 0.000 claims 1
• AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims 1
• 238000003384 imaging method Methods 0.000 claims 1
• WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 1